Compare Angi Inc (ANGI) vs Stryker Corporation (SYK) Price & Performance

ANGI trades at $6.24, down 1.89% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue of $1.03B in 2025 and net income of $43.83M, representing a 4.25% margin. Valuation metrics appear attractive with P/E of 14.85 and P/S of 0.27. Recent earnings showed a beat in Q1 2026 but misses in previous quarters, while analyst consensus price target sits at $9.20 with 33% buy ratings.

The stock presents a mixed outlook with attractive valuation multiples offset by declining revenue trends and ongoing legal investigations. Upside potential exists if the company's AI transition strategy succeeds, but risks include deteriorating core business metrics and multiple fraud investigations that could pressure shareholder value in the near term.

Stryker (SYK) trades at $329.78, up 0.82% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 63.83% gross profit margin and consistent earnings beats in recent quarters, despite a Q1 2026 miss attributed to a temporary cyber disruption. Recent news highlights the company's innovation and market position as a medtech leader.

The outlook remains positive with a consensus price target of $388.44, representing ~18% upside. Key risks include execution challenges post-cyber incident and competitive pressures, but strong cash flow and dividend growth support long-term value. Investor sentiment is buoyed by unchanged full-year guidance and healthy end-market demand.